Sovleplenib is a Small Molecule owned by Hutchison MediPharma, and is involved in 13 clinical trials, of which 5 were completed, 4 are ongoing, and 4 are planned.

Sovleplenib (HMPL-523) acts by inhibiting spleen tyrosine kinase (Syk), which is a key signaling molecule of immunoreceptor tyrosine-based activation motifs-containing immunoreceptors. Spleen tyrosine kinase (Syk), a protein tyrosine kinase implicated in the development of cancer and inflammatory disorders. It also couples B-cell receptor (BCR) activation with downstream signaling pathways, affecting cell survival and proliferation. The drug candidate, by inhibiting the Syk, elicits the required therapeutic action to treat inflammation and cancer.

The revenue for Sovleplenib is expected to reach a total of $246m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Sovleplenib NPV Report.

Sovleplenib is originated and owned by Hutchison MediPharma. Hutchmed China is the other company associated in development or marketing of Sovleplenib.

Sovleplenib Overview

Sovleplenib (HMPL-523) is under development for the treatment of hematological cancers such as relapsed and refractory Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), follicular lymphoma, coronavirus disease 2019 (COVID-19), waldenstrom macroglobulinemia, mantle cell lymphoma, multiple myeloma, diffuse large B-cell lymphoma and immunological diseases including autoimmune disorder, primary immune thrombocytopenia, Hodgkin and non-Hodgkin lymphoma, marginal zone B-cell lymphoma and autoimmune hemolytic anemia. It is administered orally as a tablet and suspension. The drug candidate targets spleen tyrosine kinase (Syk). It was also under development for acute myeloid leukemia, multiple sclerosis, lupus erythematosus and rheumatoid arthritis. The drug candidate is a new molecular entity (NME).

Hutchmed China Overview

Hutchmed China (Hutchmed) formerly known as Hutchison China MediTech is a biopharmaceutical company which discovers, develops, manufactures and commercializes drugs for the treatment of solid tumors and hematological malignancies; and immunological disorders. It also offers over-the-counter (OTC) pharmaceuticals and consumer healthcare products. Hutchmed also provides R&D services to other companies. It has a broad pipeline of drug candidates indicated for the treatment of immunological diseases, besides novel oral drug candidates for various cancers and inflammation. It operates in China, North America, Europe and Australia. The company offers prescription drugs to hospitals in China through direct sales force. It distributes consumer health products in China. Hutchmed is headquartered in Kowloon, Hong Kong.

The company reported revenues of (US Dollars) US$356.1 million for the fiscal year ended December 2021 (FY2021), an increase of 56.2% over FY2020. The operating loss of the company was US$207 million in FY2021, compared to an operating loss of US$196.7 million in FY2020. The net loss of the company was US$194.7 million in FY2021, compared to a net loss of US$125.7 million in FY2020.

Quick View – Sovleplenib

Report Segments
  • Innovator
Drug Name
  • Sovleplenib
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Hematological Disorders
  • Immunology
  • Infectious Disease
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.